SCHEMBL23770653

SCHEMBL23770653

Cc1ccccc1-c1nc(NSc2cccc(N3CCOCC3)n2)ccc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
PTK2B Q14289 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CLK4 Q9HAZ1 3/20 0.39
CLK2 P49760 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CSNK2A1 P68400 1/20 0.39
STK3 Q13188 1/20 0.39
HIPK4 Q8NE63 1/20 0.39
BRAF P15056 5/20 0.36
RAF1 P04049 4/20 0.36
ATR Q13535 2/20 0.36
ATRIP Q8WXE1 2/20 0.36
USP2 O75604 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770433 0.92 PDE10A (0.36) CNR2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL23770664 0.91 NPY5R (0.36) CNR2ALDH1A1MAPK1LMNAGAA
SCHEMBL23770859 0.90 CYP1A2 (0.44) CNR2ALDH1A1MAPK1CYP1A2CYP3A4
SCHEMBL23770663 0.89 CYP1A2 (0.43) ALDH1A1CLK4CYP1A2CYP3A4TSHR
SCHEMBL23770840 0.88 KDM4E (0.35) ALDH1A1MAPTLMNANPSR1CYP1A2
SCHEMBL23770725 0.87 CYP1A2 (0.37) ALDH1A1GSK3BCYP1A2CYP3A4ALOX15
SCHEMBL23770647 0.86 KDM4E (0.33) CNR2ALDH1A1MAPK1GAANPSR1
SCHEMBL23770723 0.86 PTPN11 (0.35) CNR2ALDH1A1MAPTLMNAGAA
SCHEMBL23770753 0.85 GRIN2B (0.36) CLK2BRAFRAF1
SCHEMBL23770673 0.83 HRH4 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed